Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) – Research analysts at Oppenheimer reduced their Q1 2020 earnings per share estimates for Biohaven Pharmaceutical in a report released on Thursday, January 23rd. Oppenheimer analyst E. Rajavelu now expects that the company will post earnings of ($2.12) per share for the quarter, down from their previous forecast of ($1.98). Oppenheimer has a “Buy” rating and a $67.00 price target on the stock. Oppenheimer also issued estimates for Biohaven Pharmaceutical’s Q2 2020 earnings at ($2.12) EPS, Q3 2020 earnings at ($2.12) EPS, Q4 2020 earnings at ($2.11) EPS, FY2020 earnings at ($8.47) EPS and FY2021 earnings at ($7.13) EPS.
Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings data on Friday, November 1st. The company reported ($2.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.47).
Several other research firms have also commented on BHVN. Wedbush initiated coverage on Biohaven Pharmaceutical in a report on Thursday, December 12th. They set an “outperform” rating and a $75.00 price target on the stock. Cantor Fitzgerald lifted their price target on Biohaven Pharmaceutical from $87.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, October 28th. Piper Jaffray Companies reiterated a “buy” rating and set a $100.00 price target on shares of Biohaven Pharmaceutical in a report on Monday, December 23rd. ValuEngine upgraded Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, December 7th. Finally, William Blair reiterated a “buy” rating on shares of Biohaven Pharmaceutical in a report on Tuesday, December 10th. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $72.25.
Shares of BHVN stock opened at $56.44 on Monday. The stock’s fifty day moving average is $54.30 and its two-hundred day moving average is $47.38. The firm has a market capitalization of $2.82 billion, a P/E ratio of -5.97 and a beta of 0.43. Biohaven Pharmaceutical has a fifty-two week low of $34.30 and a fifty-two week high of $67.86.
In related news, SVP Kimberly Gentile sold 3,935 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $53.03, for a total value of $208,673.05. Following the sale, the senior vice president now directly owns 3,935 shares in the company, valued at approximately $208,673.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Eric Aguiar sold 2,021 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $56.48, for a total transaction of $114,146.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 176,544 shares of company stock worth $9,506,726. Insiders own 23.90% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new stake in Biohaven Pharmaceutical in the 4th quarter valued at about $122,000. California Public Employees Retirement System raised its holdings in Biohaven Pharmaceutical by 119.7% in the 4th quarter. California Public Employees Retirement System now owns 139,993 shares of the company’s stock valued at $7,621,000 after buying an additional 76,265 shares during the period. Columbus Circle Investors grew its position in Biohaven Pharmaceutical by 15.9% in the 4th quarter. Columbus Circle Investors now owns 23,593 shares of the company’s stock valued at $1,284,000 after acquiring an additional 3,235 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Biohaven Pharmaceutical by 30.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,405 shares of the company’s stock valued at $185,000 after acquiring an additional 787 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB acquired a new position in Biohaven Pharmaceutical in the 4th quarter valued at about $6,805,000. Hedge funds and other institutional investors own 92.46% of the company’s stock.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Recommended Story: How Investors Can Profit from Options Trading
Receive News & Ratings for Biohaven Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.